CARBOGEN AMCIS incorporates SynProTec
CARBOGEN AMCIS, a Switzerland-based drug development chemistry company, has begun managing its newest business arm - SynProTec DCR.
CARBOGEN AMCIS, a Switzerland-based drug development chemistry company, has begun managing its newest business arm - SynProTec DCR.
The merger of the two businesses under a single management structure is expected to increase production.
SynProTec DCR specialises in process research and custom synthesis of pharmaceutical intermediates.
Meanwhile, CARBOGEN AMCIS offers a portfolio of drug-development and commercialisation services to the pharmaceutical and biopharmaceutical industry at all stages of drug development.
The move had been branded a "natural, strategic progression for both companies," according to Mark Griffiths, chief executive officer CARBOGEN AMCIS.
"We have already worked together extensively over the past six months when customers needed large quantities of intermediates," he said.
By joining the two companies under a single management structure, our production capacity will increase significantly, and material produced by SynProTec DCR can be further processed at CARBOGEN AMCIS' Swiss facilities. This will allow us even greater flexibility to accommodate projects and ensure that they are performed in the most time- and cost-efficient manner."
Also introduced to CARBOGEN AMCIS is the Laboratory Information Management System (LIMS) at Bubendorf.
Complete LIMS integration allows CARBOGEN AMCIS to share analytical data in real-time throughout the organization and directly with the customers through secure portals at all sites.
At the company's Aarau site, powder X-ray diffraction capabilities were also added for monitoring polymorphic properties, an in-demand industry capability. "We're confident that the innovative chemistry solutions we will be integrating under the new structure - as well as the recent enhancements - will benefit our customers," added Griffiths. "We look forward to formally working hand-in-hand with the expert team there. There will be continued investment at all CARBOGEN AMCIS sites, including the SynProTec DCR facility, in line with growing customer demand and the desire to remain at the forefront of scientific excellence. "
Dishman Pharmaceuticals and Chemicals own both companies.
